A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Cancer metastases; Osteosarcoma
- Focus Therapeutic Use
- Sponsors Vector Oncology Solutions LLC
- 22 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 22 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 05 Oct 2017 The company ACORN Research LLC name was changed to Vector Oncology Solutions LLC.